Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib with Atezolizumab and Bevacizumab in Advanced Cholangiocarcinoma
NCT05510427Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of infigratinib in cholangiocarcinoma (CCA) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Planned start Aug 2023; status: withdrawn.
02
Drugs
infigratinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05510427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05510427.